SAN FRANCISCO, July 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.
The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout), triggered the lawsuit which seeks to represent investors who purchased or otherwise acquired shares of Regeneron common stock between August 1, 2025 and May 15, 2026.
National shareholder rights firm Hagens Berman is investigating the legal claims and urges Regeneron investors with substantial losses to submit your losses now. The firm also invites persons who may be able to assist in the investigation to contact its attorneys.
Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action:
The litigation is focused on the propriety of Regeneron’s repeated optimism about the state of- (and changes to-) its Phase 3 trial of Fianlimab in combination with Libtayo as a first-line treatment for metastatic or locally advanced melanoma (the “Study”).
The Study’s primary endpoint was progression-free survival (“PFS”) and Regeneron has characterized the combination as a “potential blockbuster.” “Events” – disease progression or death – determined the timing and statistical power of the primary PFS analysis.
The complaint alleges that Regeneron made false and misleading statements while failing to disclose critical information to investors. In particular, the lawsuit accuses the company and its management of not informing investors that the Study’s preliminary statistical assumptions were flawed, the active treatment arm was not achieving meaningful differentiation over standard therapies, and achievement of its primary endpoint was unlikely.
Throughout the Class Period, Regeneron and the other defendants assured investors of their confidence in the Trial’s achieving its primary endpoint even when events were slowing down. At one point, management said the slowing event rates are “because the test arms are performing well.”
The truth began to emerge on April 29, 2026, when Regeneron first revealed that it decided to alter the Trial protocol such that “t]he primary analysis of progression-free survival will now consider all patients enrolled in the study with a minimum follow-up of 6 months.”
One prominent analyst reportedly questioned whether the decision was made because, in contrast to management’s expressed confidence, the “underlying PFS benefit may be insufficient to show statistical significance.”
Then, on May 12, 2026, Regeneron admitted that the decision to alter the Trial protocol was made in response to “slow event rates,” occurred nearly six months ago, and was “submitted it to all the global regulatory authorities in November, December timeframe.”
Three days later, the final blow came. On May 15, 2026, Regeneron abruptly reported the “trial did not reach statistical significance of the primary endpoint of improvement in progression-free survival (PFS).”
“We’re focused on whether Regeneron altered the Trial protocol without timely telling investors to intentionally mislead them because the defendants knew so-called blockbuster potential for the combination wasn’t really there,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the pending claims in the suit.
If you invested in Regeneron and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »
If you’d like more information and answers to other frequently asked questions about the Regeneron case and the firm’s investigation, read more »
Whistleblowers: Persons with non-public information regarding Regeneron should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
SummaryRegeneron Pharmaceuticals, Inc. remains a Buy, supported by robust revenue drivers Dupixent and Libtayo, despite recent share price volatility and underperformance versus the S&P.Dupixent’s expanding indications and sustained growth, along with Libtayo’s oncology momentum, underpin forward revenue expectations, even as Eylea faces biosimilar headwinds.Recent margin and ROIC declines are primarily due to accelerated Sanofi repayments and deferred tax asset accumulation, both expected to reverse, improving profitability from Q3 2026.REGN has a strong balance sheet, prudent capital allocation, and a deep pipeline that position REGN for a new growth phase, with operating margins and ROIC likely bottoming in 2026. Phimwilai Kitsuriya/E+ via Getty Images
Regeneron Pharmaceuticals, Inc. (REGN), based in Tarrytown, NJ, is a leading biotechnology company with a fantastic track-record of rewarding shareholders over its lifetime. However, shares have fallen from their peak of ~$1200 in August 2024 to around $660 today. The
1.24K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Regeneron (REGN) remains a Buy ahead of Q2 2026 earnings, supported by resilient Dupixent growth and strategic pipeline development. Eylea's transition to Eylea HD and Dupixent's blockbuster trajectory underpin REGN's revenue base, with Libtayo emerging as a third pillar. Pipeline setbacks (fianlimab, itepekimab) are offset by promising assets like cemdisiran, Lynozyfic, and obesity candidate olatorepatide.
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).
LOS ANGELES, July 24, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 1, 2025 and May 15, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before September 14, 2026.
New York, New York--(Newsfile Corp. - July 24, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between August 1, 2025 and May 15, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/REGN.
Regeneron Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that:
the preliminary statistical assumptions underlying Regeneron's Phase III Fianlimab-Libtayo study were fundamentally flawed; the study's active treatment arm was not demonstrating meaningful clinical differentiation from standard therapies; the study was unlikely to achieve statistical significance with respect to its primary endpoint, even absent overperformance by the control arm; and as a result, the Company's statements regarding the study's design, progress, and prospects were materially false and/or misleading at all relevant times.What's Next for Regeneron Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/REGN, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Regeneron you have until September 14, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Regeneron Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Regeneron Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305583
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
, /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.
The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout), triggered the lawsuit which seeks to represent investors who purchased or otherwise acquired shares of Regeneron common stock between August 1, 2025 and May 15, 2026.
National shareholder rights firm Hagens Berman is investigating the legal claims and urges Regeneron investors with substantial losses to submit your losses now. The firm also invites persons who may be able to assist in the investigation to contact its attorneys.
Class Period: Aug. 1, 2025 – May 15, 2026
Lead Plaintiff Deadline: Sept. 14, 2026
Visit: http://www.hbsslaw.com/investor-fraud/regn
Contact the Firm Now: [email protected]
844-916-0895
Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action:
The litigation is focused on the propriety of Regeneron's repeated optimism about the state of- (and changes to-) its Phase 3 trial of Fianlimab in combination with Libtayo as a first-line treatment for metastatic or locally advanced melanoma (the "Study").
The Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.
The complaint alleges that Regeneron made false and misleading statements while failing to disclose critical information to investors. In particular, the lawsuit accuses the company and its management of not informing investors that the Study's preliminary statistical assumptions were flawed, the active treatment arm was not achieving meaningful differentiation over standard therapies, and achievement of its primary endpoint was unlikely.
Throughout the Class Period, Regeneron and the other defendants assured investors of their confidence in the Trial's achieving its primary endpoint even when events were slowing down. At one point, management said the slowing event rates are "because the test arms are performing well."
The truth began to emerge on April 29, 2026, when Regeneron first revealed that it decided to alter the Trial protocol such that "t]he primary analysis of progression-free survival will now consider all patients enrolled in the study with a minimum follow-up of 6 months."
One prominent analyst reportedly questioned whether the decision was made because, in contrast to management's expressed confidence, the "underlying PFS benefit may be insufficient to show statistical significance."
Then, on May 12, 2026, Regeneron admitted that the decision to alter the Trial protocol was made in response to "slow event rates," occurred nearly six months ago, and was "submitted it to all the global regulatory authorities in November, December timeframe."
Three days later, the final blow came. On May 15, 2026, Regeneron abruptly reported the "trial did not reach statistical significance of the primary endpoint of improvement in progression-free survival (PFS)."
"We're focused on whether Regeneron altered the Trial protocol without timely telling investors to intentionally mislead them because the defendants knew so-called blockbuster potential for the combination wasn't really there," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the pending claims in the suit.
If you invested in Regeneron and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »
If you'd like more information and answers to other frequently asked questions about the Regeneron case and the firm's investigation, read more »
Whistleblowers: Persons with non-public information regarding Regeneron should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Regeneron between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - July 24, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (""Regeneron" or the "Company") (NASDAQ: REGN) and reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the true state of Regeneron's Phase III Fianlimab-Libtayo Study; notably, that its preliminary statistical assumptions were fundamentally flawed, that the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies, and that the trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm.
On April 29, 2026, Defendants disclosed that the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for "analysis of progression-free survival." On this news, Regeneron's stock price fell $45.41, or approximately 6.2%, to close at $686.36 per share on April 29, 2026.
On May 15, 2026, Regeneron issued a press release announcing that the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, Regeneron's stock price fell $68.57, or approximately 9.8%, to close at $629.68 per share on May 18, 2026.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Regeneron's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Regeneron class action, go to www.faruqilaw.com/REGN or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Regeneron Securities Class Action Lawsuit:
What is the Regeneron securities fraud lawsuit about?
Faruqi & Faruqi, LLP has filed a securities class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased Regeneron securities during the Class Period. The lawsuit alleges that Regeneron and certain of its officers made materially false and misleading statements regarding the Phase III Fianlimab-Libtayo clinical study. Specifically, the complaint alleges that defendants concealed that the study's preliminary statistical assumptions were fundamentally flawed, that the active treatment arm was allegedly failing to achieve meaningful clinical differentiation over standard therapies, and that the trial would ultimately fail to reach statistical significance on its primary endpoint. The alleged fraud is said to have come to light through two disclosures: first, on April 29, 2026, when defendants announced an expansion of patients eligible for analysis of progression-free survival - causing Regeneron's stock to fall approximately 6.2% - and then on May 15, 2026, when Regeneron announced that the Phase III trial did not reach statistical significance for its primary endpoint, causing the stock to fall an additional approximately 9.8%.
Who may be eligible to participate in the lawsuit?
Investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities on the NASDAQ between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), may be eligible to participate in this lawsuit. Eligibility to participate is not limited to those who seek appointment as lead plaintiff; any investor who purchased Regeneron securities during the Class Period and suffered a loss may potentially share in any recovery obtained on behalf of the class. Investors are encouraged to review their trading records to determine whether their purchases fall within the Class Period. Participation in the litigation does not require investors to take any active litigation role beyond filing a timely claim if a recovery is ultimately achieved.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff is a court-appointed representative who acts on behalf of all class members in directing the litigation, including working with counsel to make key strategic decisions regarding the case. Any investor who purchased Regeneron securities during the Class Period and suffered losses may move the court for appointment as lead plaintiff, but must do so no later than September 14, 2026, which is the court-established deadline for such motions. Courts generally appoint the movant with the largest financial interest in the relief sought who also satisfies the adequacy requirements of the applicable securities laws. Importantly, investors are not required to seek appointment as lead plaintiff in order to participate in or potentially share in any recovery that may result from this litigation. Those who do not seek lead plaintiff status may still submit a claim and may be eligible to receive a portion of any settlement or judgment obtained on behalf of the class.
What should investors do if they purchased Regeneron stock during the Class Period?
Investors who purchased Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026 are encouraged to promptly review their brokerage and trading records to confirm the timing and size of their purchases and any resulting losses. Investors should take steps to preserve all relevant documentation, including trade confirmations, account statements, and any communications relating to their Regeneron holdings, as such records may be material to any future claim. Given that the lead plaintiff motion deadline is September 14, 2026, investors who wish to be considered for that role should act in advance of that date. Investors may wish to consult with Faruqi & Faruqi, LLP to better understand their legal rights and options before the deadline passes. Retaining counsel or seeking lead plaintiff status is not required to participate in any potential class recovery, but timely action is advisable to preserve all available options.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Regeneron securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/306263
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and certain of the company’s senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws.
If you invested in Regeneron, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/regeneron-class-action-lawsuit.
Key Details of the Regeneron ($REGN) Class Action:
Lead Plaintiff Deadline: September 14, 2026Alleged Misconduct: Securities fraud alleging that Regeneron misled investors regarding the success of its Phase III Fianlimab-Libtayo clinical trialStock Drop: April 29, 2026 – 6.2% Stock DropMay 15, 2026 – 9.8% Stock Drop Court: U.S. District Court for the Southern District of New YorkAction: Contact BFA Law to discuss your rights
Investors have until September 14, 2026, to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Regeneron securities. The class action is pending in the U.S. District Court for the Southern District of New York. It is captioned Cheathem v. Regeneron Pharm., Inc., et al., No. 26-cv-6026.
Why is Regeneron Being Sued for Securities Fraud?
Regeneron is a pharmaceutical company that discovers, invents, develops, manufactures, tests, and commercializes medicines to treat various disorders.
During the relevant period, Regeneron was investigating Fianlimab, a human monoclonal antibody targeting the LAG-3 immune checkpoint receptor on T-cells. Specifically, Regeneron was testing Fianlimab in combination with Libtayo in a Phase III study to determine whether the drug combination could serve as a first-line treatment for advanced melanoma.
Regeneron told investors that it had “a lot of hope and confidence” that the Phase III trial “can generate a meaningful differentiation against current standards of care.” Further, despite acknowledging that study results had slowed, Regeneron told investors that this was likely because “there was a high level of response and those response[s] are very durable” and that the combination drug was a “potential blockbuster.”
In truth, as alleged, the Phase III Fianlimab-Libtayo study did not achieve statistically significant results.
Why did Regeneron’s Stock Drop?
On April 29, 2026, before market hours, Regeneron announced the Phase III Fianlimab-Libtayo study “will now consider all patients enrolled in the study with a minimum follow-up of 6 months.” This expansion of the study parameters indicated the study did not have enough positive results to achieve statistical significance. This news caused the price of Regeneron stock to decline $45.41 per share, or 6.2%, from a closing price of $731.77 per share on April 28, 2026, to $686.36 per share on April 29, 2026.
Then, on May 15, 2026, after market hours, Regeneron published a press release stating that the Phase III Fianlimab-Libtayo “did not reach statistical significance for the primary endpoint” tested. This news caused the price of Regeneron stock to decline $68.57 per share, or 9.8%, from a closing price of $698.25 per share on May 15, 2026, to $629.68 per share on May 18, 2026.
Click here for more information: https://www.bfalaw.com/cases/regeneron-class-action-lawsuit.
What Can You Do?
If you invested in Regeneron, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Regeneron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until September 14, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Regeneron securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On April 29, 2026, during during Regeneron's first quarter earnings call, the Company disclosed that the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for "analysis of progression-free survival."
On this news, Regeneron's stock price fell $45.41 per share, or 6.21%, to close at $686.36 per share on April 29, 2026.
Then, on May 15, 2026, Regeneron issued a press release disclosing that the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)."
On this news, Regeneron's stock price fell $68.57 per share, or 9.82%, to close at $629.68 per share on May 16, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
San Diego, California--(Newsfile Corp. - July 23, 2026) - Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Regeneron Therapeutics, Inc. (NASDAQ: REGN) from August 1, 2025 to May 15, 2026. Regeneron is a pharmaceutical company that discovers, invents, develops, manufactures, tests, and commercializes medicines to treat various disorders worldwide.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
What is the class period? August 1, 2025 – May 15, 2026
What are the allegations? Robbins LLP is Investigating Allegations that Regeneron Therapeutics, Inc. (REGN) Misled Investors Regarding the Viability of its Phase III Fianlimab-Libtayo Study
According to the complaint, during the relevant period, Regeneron was investigating Fianlimab, a human monoclonal antibody targeting the LAG-3 immune checkpoint receptor on T-cells. Fianlimab was pertinently being tested in combination with Libtayo in a phase 3 study to determine whether the drug combination could serve as a first-line treatment for advanced melanoma (the "Phase III Fianlimab-Libtayo Study"). The study had commenced enrollment in mid-2022.
Plaintiff alleges that defendants provided overwhelmingly positive statements to investors while, at the same time, concealing the true state of Regeneron's Phase III Fianlimab Libtayo Study; notably, that (i) its preliminary statistical assumptions were fundamentally flawed; (ii) the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies; and (iii) the trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm.
Plaintiff alleges that April 29, 2026, during Regeneron's first quarter earnings call, defendants disclosed the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for "analysis of progression-free survival." On this news, the price of Regeneron's common stock declined from a closing market price of $731.77 per share on April 28, 2026, to $686.36 per share on April 29, 2026, a decline of about 6.2% in the span of just a single day. Then, after-market on May 15, 2026, Regeneron announced that the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, the price of Regeneron's common stock declined from $698.25 per share on May 15, 2026, to $629.68 per share on May 18, 2026, a decline of about 9.8% in the span of one day.
What can shareholders do now? You may be eligible to participate in the class action against Regeneron Therapeutics, Inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by September 14, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP: A recognized leader in shareholder rights litigation, Robbins LLP has helped restore more than $1 billion in value to shareholders, secured some of the largest recoveries in shareholder derivative litigation history, and achieved governance reforms at over 400 Fortune 1000 companies.
"Behind everything we do is the belief that companies should be governed responsibly, fiduciaries should be held accountable, and shareholders deserve transparency and fairness," said Brian J. Robbins, Founding Partner of Robbins LLP.
To be notified if a class action against Regeneron Therapeutics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Facebook
LinkedIn
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/306109
Source: Robbins LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP alerts investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that a securities class action has been filed on behalf of shareholders who purchased securities between August 1, 2025 and May 15, 2026. Find out if you might be eligible to recover losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500. REGN traded as high as $731.77 on April 28, 2026 and closed at $629.68 after the Company announced t.
Regeneron's clinical-trial risk disclosures are under scrutiny after allegations that the Company minimized Phase III Fianlimab-Libtayo statistical and protocol risks, including potential impact of FDA Otptimus-related amendments on progression-free survival analysis.
, /PRNewswire/ -- SueWallSt alerts investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that a securities class action has been filed on behalf of shareholders who purchased REGN securities between August 1, 2025 and May 15, 2026. Submit your information now.
REGN shares allegedly declined $102.09 per share, or 13.95%, from the Class Period high of $731.77 on April 28, 2026 to $629.68 after disclosures concerning the Phase III Fianlimab-Libtayo Study. IMPORTANT DATE: September 14, 2026 is the deadline for investors seeking appointment as lead plaintiff.
Regulatory Compliance Risk Allegedly Became Investor Loss
The complaint challenges whether Regeneron adequately disclosed the clinical, statistical, and regulatory risks surrounding its Phase III Fianlimab-Libtayo Study. The case alleges that public statements minimized the risk that slowing event accrual reflected flaws in preliminary statistical assumptions, rather than durable efficacy in the active treatment arms.
As alleged, Regeneron's study design also had to account for FDA Optimus requirements concerning dose contribution. The lawsuit contends that the Company's statements did not sufficiently disclose that the active treatment arm was allegedly failing to show meaningful differentiation over standard therapies.
Disclosure Gaps Alleged in the Phase III Study
The action claims investors were not adequately informed that:
The prolonged slowdown in progression-free survival event accrual allegedly increased the risk of clinical failure. The study's statistical assumptions and design left it more vulnerable to missing its primary endpoint. The active treatment arm allegedly lacked meaningful clinical differentiation over pembrolizumab and other standard therapies. A protocol amendment expanded the PFS analysis population to include all patients with at least 6 months of follow-up. The study ultimately did not reach statistical significance for its primary endpoint of improved PFS. Alleged SEC Disclosure Adequacy Issues
The complaint alleges that Regeneron's public disclosures mischaracterized the actual risk of failure facing the study and minimized risks to the study's odds of achieving its primary endpoint and overall statistical validity. On April 29, 2026, Regeneron disclosed that the protocol had been changed to expand the eligible patient group for PFS analysis.
On May 15, 2026, after market close, Regeneron announced that the Phase 3 Trial of Fianlimab did not reach statistical significance for the primary endpoint of improvement in PFS. The lawsuit alleges these disclosures corrected earlier alleged misstatements and caused investors to suffer losses.
"Generic risk factor language cannot substitute for disclosing specific, known problems that are already affecting a company's operations. Here, investors should review whether the alleged protocol, statistical, and FDA Optimus-related protocol amendment risks were adequately disclosed before REGN shares declined." -- Joseph E. Levi, Esq.
Find out if you might qualify to recover losses
WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the REGN Lawsuit
Q: What is the REGN class action lawsuit about? A: A securities class action has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) alleging materially false and misleading statements between August 1, 2025 and May 15, 2026. Shares fell approximately 13.95% after the Company disclosed a protocol amendment and later announced that the Phase 3 Fianlimab trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival. Investors who purchased shares during the Class Period and suffered losses may be eligible to seek compensation.
Q: What specific misstatements does the REGN lawsuit allege? A: The complaint alleges Regeneron made materially false or misleading statements regarding the Phase III Fianlimab-Libtayo Study, including statements that allegedly characterized slowing event accrual as a potentially favorable sign while minimizing statistical validity and clinical-failure risks. When the protocol amendment and failed primary endpoint were disclosed, the stock price declined sharply.
Q: What court was the REGN class action filed in? A: The case was filed in the United States District Court for the Southern District of New York and is governed by the Private Securities Litigation Reform Act of 1995.
Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.
Q: What documents do I need to submit my information? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my REGN shares, can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.
Q: What does it cost me to participate? A: There is no upfront cost to contact the firm. Securities class actions are generally handled on a pure contingency basis. No upfront fees, no retainer, and no out-of-pocket costs. Any attorneys' fees and expenses awarded to class counsel are subject to court approval.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (888) SueWallSt
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
Regeneron (REGN - Free Report) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 30. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus EstimateThis biopharmaceutical company is expected to post quarterly earnings of $10.00 per share in its upcoming report, which represents a year-over-year change of -22.4%.
Revenues are expected to be $3.84 billion, up 4.5% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.3% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Regeneron?For Regeneron, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +1.22%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination indicates that Regeneron will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Regeneron would post earnings of $8.52 per share when it actually produced earnings of $9.47, delivering a surprise of +11.15%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Regeneron appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) between August 1, 2025 and May 15, 2026, inclusive. Should You Join The Regeneron Class Action Lawsuit : Do you, or did you, own shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)?
NEW YORK--(BUSINESS WIRE)---- $REGN #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. ("“Regeneron” or the “Company”) (NASDAQ: REGN) and reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California an.
New York, New York--(Newsfile Corp. - July 22, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between August 1, 2025 and May 15, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/REGN.
Regeneron Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that:
the preliminary statistical assumptions underlying Regeneron's Phase III Fianlimab-Libtayo study were fundamentally flawed; the study's active treatment arm was not demonstrating meaningful clinical differentiation from standard therapies; the study was unlikely to achieve statistical significance with respect to its primary endpoint, even absent overperformance by the control arm; and as a result, the Company's statements regarding the study's design, progress, and prospects were materially false and/or misleading at all relevant times.What's Next for Regeneron Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/REGN, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Regeneron you have until September 14, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Regeneron Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Regeneron Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305582
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
, /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between August 1, 2025 and May 15, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/REGN.
Regeneron Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that:
the preliminary statistical assumptions underlying Regeneron's Phase III Fianlimab-Libtayo study were fundamentally flawed; the study's active treatment arm was not demonstrating meaningful clinical differentiation from standard therapies; the study was unlikely to achieve statistical significance with respect to its primary endpoint, even absent overperformance by the control arm; and as a result, the Company's statements regarding the study's design, progress, and prospects were materially false and/or misleading at all relevant times. What's Next for Regeneron Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/REGN. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Regeneron you have until September 14, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Regeneron Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Regeneron Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.
The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout), triggered the lawsuit which seeks to represent investors who purchased or otherwise acquired shares of Regeneron common stock between August 1, 2025 and May 15, 2026.
National shareholder rights firm Hagens Berman is investigating the legal claims and urges Regeneron investors with substantial losses to submit your losses now. The firm also invites persons who may be able to assist in the investigation to contact its attorneys.
Class Period: Aug. 1, 2025 – May 15, 2026
Lead Plaintiff Deadline: Sept. 14, 2026
Visit: http://www.hbsslaw.com/investor-fraud/regn
Contact the Firm Now: [email protected]
844-916-0895
Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action:
The litigation is focused on the propriety of Regeneron's repeated optimism about the state of- (and changes to-) its Phase 3 trial of Fianlimab in combination with Libtayo as a first-line treatment for metastatic or locally advanced melanoma (the "Study").
The Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.
The complaint alleges that Regeneron made false and misleading statements while failing to disclose critical information to investors. In particular, the lawsuit accuses the company and its management of not informing investors that the Study's preliminary statistical assumptions were flawed, the active treatment arm was not achieving meaningful differentiation over standard therapies, and achievement of its primary endpoint was unlikely.
Throughout the Class Period, Regeneron and the other defendants assured investors of their confidence in the Trial's achieving its primary endpoint even when events were slowing down. At one point, management said the slowing event rates are "because the test arms are performing well."
The truth began to emerge on April 29, 2026, when Regeneron first revealed that it decided to alter the Trial protocol such that "t]he primary analysis of progression-free survival will now consider all patients enrolled in the study with a minimum follow-up of 6 months."
One prominent analyst reportedly questioned whether the decision was made because, in contrast to management's expressed confidence, the "underlying PFS benefit may be insufficient to show statistical significance."
Then, on May 12, 2026, Regeneron admitted that the decision to alter the Trial protocol was made in response to "slow event rates," occurred nearly six months ago, and was "submitted it to all the global regulatory authorities in November, December timeframe."
Three days later, the final blow came. On May 15, 2026, Regeneron abruptly reported the "trial did not reach statistical significance of the primary endpoint of improvement in progression-free survival (PFS)."
"We're focused on whether Regeneron altered the Trial protocol without timely telling investors to intentionally mislead them because the defendants knew so-called blockbuster potential for the combination wasn't really there," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the pending claims in the suit.
If you invested in Regeneron and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »
If you'd like more information and answers to other frequently asked questions about the Regeneron case and the firm's investigation, read more »
Whistleblowers: Persons with non-public information regarding Regeneron should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) of the September 14, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company.
Should You Join The Regeneron Class Action Lawsuit:
Do you, or did you, own shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)?Did you purchase your shares between August 1, 2025 and May 15, 2026, inclusive?Did you lose money in your investment in Regeneron Pharmaceuticals, Inc.? Investors are encouraged to act promptly and submit a form at Regeneron Pharmaceuticals, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected].
If you wish to serve as lead plaintiff for the Class, you must file papers by September 14, 2026. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About The Lawsuit:
A lawsuit was filed on behalf of investors (the “Class”) who purchased or acquired the common stock of Regeneron between August 1, 2025 and May 15, 2026, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.
The lawsuit alleges that defendants made materially false and misleading statements and omissions regarding the Company’s business operations, growth prospects, and financial stability. As a result of these alleged misrepresentations, Regeneron common stock traded at artificially inflated prices during the Class Period. When the truth was disclosed, investors allegedly suffered significant losses.
About Bernstein Liebhard:
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and certain of the company’s senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws.
If you invested in Regeneron, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/regeneron-class-action-lawsuit.
Key Details of the Regeneron ($REGN) Class Action:
Lead Plaintiff Deadline: September 14, 2026Alleged Misconduct: Securities fraud alleging that Regeneron misled investors regarding the success of its Phase III Fianlimab-Libtayo clinical trialStock Drop: April 29, 2026 – 6.2% Stock DropMay 15, 2026 – 9.8% Stock Drop Court: U.S. District Court for the Southern District of New YorkAction: Contact BFA Law to discuss your rights Investors have until September 14, 2026, to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Regeneron securities. The class action is pending in the U.S. District Court for the Southern District of New York. It is captioned Cheathem v. Regeneron Pharm., Inc., et al., No. 26-cv-6026.
Why is Regeneron Being Sued for Securities Fraud?
Regeneron is a pharmaceutical company that discovers, invents, develops, manufactures, tests, and commercializes medicines to treat various disorders.
During the relevant period, Regeneron was investigating Fianlimab, a human monoclonal antibody targeting the LAG-3 immune checkpoint receptor on T-cells. Specifically, Regeneron was testing Fianlimab in combination with Libtayo in a Phase III study to determine whether the drug combination could serve as a first-line treatment for advanced melanoma.
Regeneron told investors that it had “a lot of hope and confidence” that the Phase III trial “can generate a meaningful differentiation against current standards of care.” Further, despite acknowledging that study results had slowed, Regeneron told investors that this was likely because “there was a high level of response and those response[s] are very durable” and that the combination drug was a “potential blockbuster.”
In truth, as alleged, the Phase III Fianlimab-Libtayo study did not achieve statistically significant results.
Why did Regeneron’s Stock Drop?
On April 29, 2026, before market hours, Regeneron announced the Phase III Fianlimab-Libtayo study “will now consider all patients enrolled in the study with a minimum follow-up of 6 months.” This expansion of the study parameters indicated the study did not have enough positive results to achieve statistical significance. This news caused the price of Regeneron stock to decline $45.41 per share, or 6.2%, from a closing price of $731.77 per share on April 28, 2026, to $686.36 per share on April 29, 2026.
Then, on May 15, 2026, after market hours, Regeneron published a press release stating that the Phase III Fianlimab-Libtayo “did not reach statistical significance for the primary endpoint” tested. This news caused the price of Regeneron stock to decline $68.57 per share, or 9.8%, from a closing price of $698.25 per share on May 15, 2026, to $629.68 per share on May 18, 2026.
Click here for more information: https://www.bfalaw.com/cases/regeneron-class-action-lawsuit.
What Can You Do?
If you invested in Regeneron, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
NEW YORK--(BUSINESS WIRE)---- $REGN #BFA--Regeneron Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA.
, /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.
The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout), triggered the lawsuit which seeks to represent investors who purchased or otherwise acquired shares of Regeneron common stock between August 1, 2025 and May 15, 2026.
National shareholder rights firm Hagens Berman is investigating the legal claims and urges Regeneron investors with substantial losses to submit your losses now. The firm also invites persons who may be able to assist in the investigation to contact its attorneys.
Class Period: Aug. 1, 2025 – May 15, 2026
Lead Plaintiff Deadline: Sept. 14, 2026
Visit: http://www.hbsslaw.com/investor-fraud/regn
Contact the Firm Now: [email protected]
844-916-0895
Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action:
The litigation is focused on the propriety of Regeneron's repeated optimism about the state of- (and changes to-) its Phase 3 trial of Fianlimab in combination with Libtayo as a first-line treatment for metastatic or locally advanced melanoma (the "Study").
The Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.
The complaint alleges that Regeneron made false and misleading statements while failing to disclose critical information to investors. In particular, the lawsuit accuses the company and its management of not informing investors that the Study's preliminary statistical assumptions were flawed, the active treatment arm was not achieving meaningful differentiation over standard therapies, and achievement of its primary endpoint was unlikely.
Throughout the Class Period, Regeneron and the other defendants assured investors of their confidence in the Trial's achieving its primary endpoint even when events were slowing down. At one point, management said the slowing event rates are "because the test arms are performing well."
The truth began to emerge on April 29, 2026, when Regeneron first revealed that it decided to alter the Trial protocol such that "t]he primary analysis of progression-free survival will now consider all patients enrolled in the study with a minimum follow-up of 6 months."
One prominent analyst reportedly questioned whether the decision was made because, in contrast to management's expressed confidence, the "underlying PFS benefit may be insufficient to show statistical significance."
Then, on May 12, 2026, Regeneron admitted that the decision to alter the Trial protocol was made in response to "slow event rates," occurred nearly six months ago, and was "submitted it to all the global regulatory authorities in November, December timeframe."
Three days later, the final blow came. On May 15, 2026, Regeneron abruptly reported the "trial did not reach statistical significance of the primary endpoint of improvement in progression-free survival (PFS)."
"We're focused on whether Regeneron altered the Trial protocol without timely telling investors to intentionally mislead them because the defendants knew so-called blockbuster potential for the combination wasn't really there," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the pending claims in the suit.
If you invested in Regeneron and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »
If you'd like more information and answers to other frequently asked questions about the Regeneron case and the firm's investigation, read more »
Whistleblowers: Persons with non-public information regarding Regeneron should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Regeneron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until September 14, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Regeneron securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On April 29, 2026, during during Regeneron’s first quarter earnings call, the Company disclosed that the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for “analysis of progression-free survival.”
On this news, Regeneron’s stock price fell $45.41 per share, or 6.21%, to close at $686.36 per share on April 29, 2026.
Then, on May 15, 2026, Regeneron issued a press release disclosing that the “Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS).”
On this news, Regeneron’s stock price fell $68.57 per share, or 9.82%, to close at $629.68 per share on May 16, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- SueWallSt notifies investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that a class action has been filed on behalf of shareholders who purchased securities between August 1, 2025 and May 15, 2026. Find out if you could qualify to recover your per-share losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.
REGN declined from a Class Period high of $731.77 on April 28, 2026 to $629.68 after the May 15, 2026 after-market announcement, a $102.09 per-share decline, or approximately 13.95%. The lead plaintiff deadline is September 14, 2026.
Ryan Crowe Regeneron Securities Defendant Liability Allegations
As named in the action, Ryan Crowe served as Regeneron's Senior Vice President of Investor Relations and Strategic Analysis during the Class Period. The complaint identifies investor-facing presentations in which Crowe allegedly discussed the Phase III Fianlimab-Libtayo Study, prior Phase I results, expectations for progression-free survival, and the significance of slowing event accrual.
The action claims those communications contributed to an allegedly misleading impression that the study remained positioned to demonstrate meaningful clinical differentiation over existing standards of care. Plaintiffs allege that investors were not adequately informed that the prolonged event-rate slowdown reflected heightened risk to the trial's statistical validity and primary endpoint.
Crowe's Alleged Role in Investor Communications
Crowe is named as an individual defendant in the securities action.The complaint identifies his role in discussing Regeneron's oncology pipeline with investors and analysts.His alleged statements referenced Phase I pooled results, including a 57% objective response rate and 24-month median progression-free survival.Plaintiffs claim the public messaging understated the risk that the Phase III study would fail to show statistically significant PFS improvement.The complaint alleges the later protocol expansion and failed primary endpoint corrected prior alleged misstatements. Accountability Questions Raised by the Filing
The securities action asserts claims under Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5. As pleaded, Crowe's investor-relations function is relevant because the challenged statements were allegedly directed to the market during a period when REGN shares traded at prices plaintiffs claim were artificially inflated.
"Individual officers who communicate with investors about clinical-trial progress should ensure those statements are accurate, complete, and appropriately qualified. Here, the action alleges that public commentary about PFS event accrual and clinical differentiation did not match the risks facing the Phase III study." -- Joseph E. Levi, Esq.
Submit your information here or call (888) SueWallSt.
WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the REGN Lawsuit
Q: What is the REGN class action lawsuit about? A: A securities class action has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) alleging materially false and misleading statements between August 1, 2025 and May 15, 2026. Shares fell approximately 13.95% from the Class Period high after the Company disclosed a protocol amendment and later announced that the Phase III Fianlimab-Libtayo Study did not reach statistical significance for its primary PFS endpoint.
Q: Who may be eligible in the REGN investor lawsuit? A: Investors who purchased REGN stock or securities between August 1, 2025 and May 15, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.
Q: What court was the REGN class action filed in? A: The case was filed in the United States District Court for the Southern District of New York and is governed by the Private Securities Litigation Reform Act of 1995.
Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.
Q: What documents are useful for evaluating REGN losses? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices are typically useful for evaluating potential losses.
Q: What if I already sold my REGN shares, can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.
Q: What does it cost me to participate? A: There is no upfront cost to contact the firm. Securities class actions are generally handled on a pure contingency basis. No upfront fees, no retainer, and no out-of-pocket costs. Any attorneys' fees and expenses awarded to class counsel are subject to court approval.
, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).
Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Regeneron's Phase III Fianlimab-Libtayo Study; notably, that its preliminary statistical assumptions were fundamentally flawed, that the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies, and that the trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm. On April 29, 2026, during Regeneron's first quarter earnings call, defendants disclosed the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for "analysis of progression-free survival." Following this news, the price of Regeneron's common stock declined dramatically. From a closing market price of $731.77 per share on April 28, 2026, Regeneron's stock price fell to $686.36 per share on April 29, 2026, a decline of about 6.2% in the span of just a single day. On May 15, 2026, Regeneron issued a press release announcing that the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." Following this news, the price of Regeneron's common stock declined even further. From a closing market price of $698.25 per share on May 15, 2026, Regeneron's stock price fell to $629.68 per share on May 18, 2026, a decline of about 9.8% in the span of one day.
DEADLINE: September 14, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/regeneron-pharmaceuticals-inc-loss-submission-form-2/?id=194990&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of REGN during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is September 14, 2026. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903
LOS ANGELES, July 21, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company’s securities between August 1, 2025 and May 15, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before September 14, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Regeneron led investors to believe that its Phase III Fianlimab-Libtayo Study was likely to succeed by achieving its primary endpoint. The Company utilized flawed statistical assumptions. In fact, the Company failed to demonstrate clinical differentiation from other therapies. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Regeneron, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335 [email protected]
Assetmark Inc. boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 9.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 12,316 shares of the biopharmaceutical company’s stock after purchasing an additional 1,036 shares during the period. Assetmark Inc.’s holdings in Regeneron Pharmaceuticals were worth $9,516,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. Norges Bank bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $1,012,296,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Regeneron Pharmaceuticals by 142.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock worth $1,504,991,000 after purchasing an additional 1,144,887 shares during the last quarter. Nuveen LLC increased its stake in shares of Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after buying an additional 835,240 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Regeneron Pharmaceuticals by 8,620.0% in the fourth quarter. Wellington Management Group LLP now owns 664,465 shares of the biopharmaceutical company’s stock valued at $512,881,000 after buying an additional 656,845 shares in the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 528.7% in the third quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock worth $405,596,000 after acquiring an additional 606,612 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.
Regeneron Pharmaceuticals Stock Performance Shares of REGN stock opened at $672.15 on Tuesday. The company has a market capitalization of $71.06 billion, a P/E ratio of 16.38, a price-to-earnings-growth ratio of 1.50 and a beta of 0.24. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $821.11. The company’s 50 day moving average price is $640.18 and its two-hundred day moving average price is $717.26.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s revenue was up 19.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $8.22 EPS. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.12 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals Announces Dividend The firm also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is 9.16%.
Insiders Place Their Bets In related news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.
Wall Street Analyst Weigh In A number of research analysts have commented on the company. HSBC decreased their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Royal Bank Of Canada decreased their price target on Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 7th. Guggenheim lifted their price objective on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a research report on Friday, May 1st. Finally, Morgan Stanley dropped their price objective on Regeneron Pharmaceuticals from $788.00 to $730.00 and set an “equal weight” rating for the company in a report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $787.67.
Read Our Latest Stock Analysis on Regeneron Pharmaceuticals
Key Stories Impacting Regeneron Pharmaceuticals Here are the key news stories impacting Regeneron Pharmaceuticals this week:
Negative Sentiment: Multiple law firms, including Bernstein Liebhard, Levi & Korsinsky, the Schall Law Firm, the DJS Law Group, Faruqi & Faruqi, and Bronstein, Gewirtz & Grossman, announced or reminded investors about a class action lawsuit against Regeneron Pharmaceuticals, Inc. (REGN), with a lead plaintiff deadline of September 14, 2026. These notices suggest potential litigation risk and uncertainty for shareholders. Article Title Negative Sentiment: The lawsuit coverage increases headline risk and could weigh on sentiment until more details emerge about the alleged claims and the company’s response. Article Title Neutral Sentiment: The company previously reported strong quarterly results, including earnings and revenue that beat expectations, which remains a supportive backdrop for the stock even as legal issues dominate near-term trading. MarketBeat About Regeneron Pharmaceuticals (Free Report)
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Read More Five stocks we like better than Regeneron Pharmaceuticals The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAndra AP fonden Has $19.06 Million Stake in Robinhood Markets, Inc. $HOOD
NEXT HEADLINE »Angeles Wealth Management LLC Purchases 3,960 Shares of Alphabet Inc. $GOOG
Baader Bank Aktiengesellschaft boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 138.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,811 shares of the biopharmaceutical company’s stock after purchasing an additional 3,958 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Regeneron Pharmaceuticals were worth $5,262,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in REGN. Nordea Investment Management AB grew its holdings in shares of Regeneron Pharmaceuticals by 118.1% during the fourth quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock valued at $105,810,000 after buying an additional 74,350 shares during the last quarter. Lockheed Martin Investment Management Co. purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $2,702,000. Asio Capital LLC purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $3,422,000. Robeco Institutional Asset Management B.V. lifted its position in Regeneron Pharmaceuticals by 116.6% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 261,850 shares of the biopharmaceutical company’s stock valued at $202,114,000 after acquiring an additional 140,966 shares in the last quarter. Finally, National Pension Service lifted its position in Regeneron Pharmaceuticals by 29.8% in the 4th quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock valued at $278,636,000 after acquiring an additional 82,853 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.
Key Headlines Impacting Regeneron Pharmaceuticals Here are the key news stories impacting Regeneron Pharmaceuticals this week:
Negative Sentiment: Multiple law firms, including Bernstein Liebhard, Levi & Korsinsky, the Schall Law Firm, the DJS Law Group, Faruqi & Faruqi, and Bronstein, Gewirtz & Grossman, announced or reminded investors about a class action lawsuit against Regeneron Pharmaceuticals, Inc. (REGN), with a lead plaintiff deadline of September 14, 2026. These notices suggest potential litigation risk and uncertainty for shareholders. Article Title Negative Sentiment: The lawsuit coverage increases headline risk and could weigh on sentiment until more details emerge about the alleged claims and the company’s response. Article Title Neutral Sentiment: The company previously reported strong quarterly results, including earnings and revenue that beat expectations, which remains a supportive backdrop for the stock even as legal issues dominate near-term trading. MarketBeat Analyst Upgrades and Downgrades REGN has been the subject of a number of research analyst reports. Guggenheim lifted their target price on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a report on Friday, May 1st. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Wells Fargo & Company lowered their price target on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a report on Monday, May 18th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Finally, Royal Bank Of Canada reduced their price objective on Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating for the company in a report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $787.67.
View Our Latest Report on Regeneron Pharmaceuticals
Insider Activity at Regeneron Pharmaceuticals In related news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by insiders.
Regeneron Pharmaceuticals Trading Down 0.7% Shares of REGN stock opened at $672.15 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $541.00 and a 12-month high of $821.11. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The firm’s 50 day moving average is $640.18 and its 200 day moving average is $717.26. The stock has a market capitalization of $71.06 billion, a P/E ratio of 16.38, a P/E/G ratio of 1.50 and a beta of 0.24.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same period in the previous year, the business earned $8.22 EPS. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.12 earnings per share for the current year.
Regeneron Pharmaceuticals Announces Dividend The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were issued a $0.94 dividend. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.
Regeneron Pharmaceuticals Company Profile (Free Report)
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Featured Stories Five stocks we like better than Regeneron Pharmaceuticals The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAngeles Wealth Management LLC Purchases 3,960 Shares of Alphabet Inc. $GOOG
NEXT HEADLINE »Arbor Trust Wealth Advisors LLC Decreases Stock Position in Apple Inc. $AAPL
AlTi Global Inc. boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 312.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,857 shares of the biopharmaceutical company’s stock after purchasing an additional 1,407 shares during the period. AlTi Global Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,435,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Nordea Investment Management AB increased its position in shares of Regeneron Pharmaceuticals by 118.1% in the fourth quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock worth $105,810,000 after acquiring an additional 74,350 shares in the last quarter. Lockheed Martin Investment Management Co. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $2,702,000. Asio Capital LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $3,422,000. Robeco Institutional Asset Management B.V. boosted its stake in Regeneron Pharmaceuticals by 116.6% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 261,850 shares of the biopharmaceutical company’s stock worth $202,114,000 after purchasing an additional 140,966 shares during the period. Finally, National Pension Service grew its position in Regeneron Pharmaceuticals by 29.8% during the 4th quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock worth $278,636,000 after purchasing an additional 82,853 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.
Insider Buying and Selling at Regeneron Pharmaceuticals In related news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.
Regeneron Pharmaceuticals Trading Down 0.7% Shares of NASDAQ:REGN opened at $672.15 on Tuesday. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $71.06 billion, a PE ratio of 16.38, a P/E/G ratio of 1.50 and a beta of 0.24. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $821.11. The firm has a fifty day moving average price of $640.18 and a 200 day moving average price of $717.26.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business’s revenue was up 19.0% compared to the same quarter last year. During the same period last year, the company earned $8.22 earnings per share. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current fiscal year.
Regeneron Pharmaceuticals Announces Dividend The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.
Wall Street Analyst Weigh In A number of analysts have recently issued reports on REGN shares. HSBC reduced their target price on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a report on Monday, July 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Royal Bank Of Canada decreased their price objective on Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating for the company in a research report on Tuesday, July 7th. Canaccord Genuity Group lowered their target price on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Finally, Sanford C. Bernstein reduced their price target on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research report on Wednesday, April 8th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $787.67.
View Our Latest Analysis on Regeneron Pharmaceuticals
Key Stories Impacting Regeneron Pharmaceuticals Here are the key news stories impacting Regeneron Pharmaceuticals this week:
Negative Sentiment: Multiple law firms, including Bernstein Liebhard, Levi & Korsinsky, the Schall Law Firm, the DJS Law Group, Faruqi & Faruqi, and Bronstein, Gewirtz & Grossman, announced or reminded investors about a class action lawsuit against Regeneron Pharmaceuticals, Inc. (REGN), with a lead plaintiff deadline of September 14, 2026. These notices suggest potential litigation risk and uncertainty for shareholders. Article Title Negative Sentiment: The lawsuit coverage increases headline risk and could weigh on sentiment until more details emerge about the alleged claims and the company’s response. Article Title Neutral Sentiment: The company previously reported strong quarterly results, including earnings and revenue that beat expectations, which remains a supportive backdrop for the stock even as legal issues dominate near-term trading. MarketBeat Regeneron Pharmaceuticals Profile (Free Report)
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
See Also Five stocks we like better than Regeneron Pharmaceuticals The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAlTi Global Inc. Makes New Investment in Establishment Labs Holdings Inc. $ESTA
NEXT HEADLINE »AlTi Global Inc. Has $1.14 Million Holdings in Paramount Skydance Corporation $PSKY
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) between August 1, 2025 and May 15, 2026, inclusive.
What To Do Next:
Investors are encouraged to act promptly and submit a form at Regeneron Pharmaceuticals, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected].
If you wish to serve as lead plaintiff for the Class, you must file papers by September 14, 2026. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About The Lawsuit:
The lawsuit alleges that defendants made materially false and misleading statements and omissions regarding the Company’s business operations, growth prospects, and financial stability. As a result of these alleged misrepresentations, Regeneron common stock traded at artificially inflated prices during the Class Period. When the truth was disclosed, investors allegedly suffered significant losses.
About Bernstein Liebhard:
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Regeneron between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - July 20, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (""Regeneron" or the "Company") (NASDAQ: REGN) and reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the true state of Regeneron's Phase III Fianlimab-Libtayo Study; notably, that its preliminary statistical assumptions were fundamentally flawed, that the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies, and that the trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm.
On April 29, 2026, Defendants disclosed that the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for "analysis of progression-free survival." On this news, Regeneron's stock price fell $45.41, or approximately 6.2%, to close at $686.36 per share on April 29, 2026.
On May 15, 2026, Regeneron issued a press release announcing that the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, Regeneron's stock price fell $68.57, or approximately 9.8%, to close at $629.68 per share on May 18, 2026.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Regeneron's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Regeneron class action, go to www.faruqilaw.com/REGN or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Regeneron Securities Class Action Lawsuit:
What is the Regeneron securities fraud lawsuit about?
Faruqi & Faruqi, LLP has filed a securities class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased Regeneron securities during the Class Period. The lawsuit alleges that Regeneron and certain of its officers made materially false and misleading statements regarding the Phase III Fianlimab-Libtayo clinical study. Specifically, the complaint alleges that defendants concealed that the study's preliminary statistical assumptions were fundamentally flawed, that the active treatment arm was allegedly failing to achieve meaningful clinical differentiation over standard therapies, and that the trial would ultimately fail to reach statistical significance on its primary endpoint. The alleged fraud is said to have come to light through two disclosures: first, on April 29, 2026, when defendants announced an expansion of patients eligible for analysis of progression-free survival — causing Regeneron's stock to fall approximately 6.2% — and then on May 15, 2026, when Regeneron announced that the Phase III trial did not reach statistical significance for its primary endpoint, causing the stock to fall an additional approximately 9.8%.
Who may be eligible to participate in the lawsuit?
Investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities on the NASDAQ between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), may be eligible to participate in this lawsuit. Eligibility to participate is not limited to those who seek appointment as lead plaintiff; any investor who purchased Regeneron securities during the Class Period and suffered a loss may potentially share in any recovery obtained on behalf of the class. Investors are encouraged to review their trading records to determine whether their purchases fall within the Class Period. Participation in the litigation does not require investors to take any active litigation role beyond filing a timely claim if a recovery is ultimately achieved.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff is a court-appointed representative who acts on behalf of all class members in directing the litigation, including working with counsel to make key strategic decisions regarding the case. Any investor who purchased Regeneron securities during the Class Period and suffered losses may move the court for appointment as lead plaintiff, but must do so no later than September 14, 2026, which is the court-established deadline for such motions. Courts generally appoint the movant with the largest financial interest in the relief sought who also satisfies the adequacy requirements of the applicable securities laws. Importantly, investors are not required to seek appointment as lead plaintiff in order to participate in or potentially share in any recovery that may result from this litigation. Those who do not seek lead plaintiff status may still submit a claim and may be eligible to receive a portion of any settlement or judgment obtained on behalf of the class.
What should investors do if they purchased Regeneron stock during the Class Period?
Investors who purchased Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026 are encouraged to promptly review their brokerage and trading records to confirm the timing and size of their purchases and any resulting losses. Investors should take steps to preserve all relevant documentation, including trade confirmations, account statements, and any communications relating to their Regeneron holdings, as such records may be material to any future claim. Given that the lead plaintiff motion deadline is September 14, 2026, investors who wish to be considered for that role should act in advance of that date. Investors may wish to consult with Faruqi & Faruqi, LLP to better understand their legal rights and options before the deadline passes. Retaining counsel or seeking lead plaintiff status is not required to participate in any potential class recovery, but timely action is advisable to preserve all available options.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Regeneron securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305844
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP alerts investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that a securities class action has been filed on behalf of shareholders who purchased securities between August 1, 2025 and May 15, 2026. Check if you might be eligible to recover your investment losses.
April 29, 2026: REGN declined from $731.77 to $686.36, a $45.41 per-share drop, or about 6.2%. May 18, 2026: REGN declined from $698.25 to $629.68, a $68.57 per-share drop, or about 9.8%. From the Class Period high, REGN lost $102.09 per share, or 13.95%. Lead plaintiff applications must be submitted by September 14, 2026.
Wall Street Reaction After the Protocol Amendment
The complaint alleges that Regeneron and certain executives minimized the significance of a prolonged slowdown in progression-free survival event accrual in the Phase III Fianlimab-Libtayo Study. On April 29, 2026, the Company disclosed that the primary analysis of progression-free survival would consider all enrolled patients with at least 6 months of follow-up.
Analysts allegedly reacted to that disclosure as a meaningful change in the study's risk profile. Wells Fargo reportedly cut its price target by 3% and stated that investor concern centered on whether expanding the PFS cohort suggested that the underlying benefit may be insufficient to show statistical significance.
Analyst Coverage Timeline
Wells Fargo attributed REGN's April 29 share decline primarily to the Company's decision to expand the PFS cohort.The coverage indicated investor concern that the change could signal insufficient PFS benefit.Evercore ISI noted that a protocol amendment appeared necessary to support the timing of the readout.Evercore analysts allegedly observed that Regeneron's preliminary assumptions were materially off after the delay and amendment.The complaint contends that these analyst reactions called into question earlier positive statements about event accrual and study confidence. Execution Concerns on Wall Street
As alleged, the analyst commentary focused less on the quarterly earnings backdrop and more on the clinical trial implications of the protocol change. The action claims the amendment raised questions about whether the study's original statistical assumptions and endpoint timing were reliable.
"When analyst expectations are built on incomplete or allegedly misleading company disclosures, the resulting corrections can cause significant investor harm. Here, the analyst reaction cited in the complaint is important because it connects the protocol amendment to investor concerns about statistical significance and trial execution." -- Joseph E. Levi, Esq.
Learn more about the case
WHY LEVI & KORSINSKY — Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.
Frequently Asked Questions About the REGN Lawsuit
Q: What is the REGN class action lawsuit about? A: A securities class action has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) alleging materially false and misleading statements between August 1, 2025 and May 15, 2026. Shares fell approximately 13.95% from the Class Period high after the Company disclosed a Phase III Fianlimab-Libtayo protocol amendment and later announced that the trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival.
Q: How much did REGN stock drop? A: REGN shares fell $102.09 per share, or 13.95%, from the Class Period high of $731.77 on April 28, 2026 to $629.68 after the May 15, 2026 after-market announcement. Investors who purchased during the Class Period at allegedly inflated prices and suffered losses may be eligible to seek compensation.
Q: What is the REGN lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is September 14, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.
Q: What if I already sold my REGN shares – can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.
Q: What does it cost me to participate? A: There is no upfront cost to contact the firm. Securities class actions are generally handled on a pure contingency basis. No upfront fees, no retainer, and no out-of-pocket costs. Any attorneys' fees and expenses awarded to class counsel are subject to court approval.
Q: What do REGN investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as an absent class member.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004 [email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before September 14, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Regeneron led investors to believe that its Phase III Fianlimab-Libtayo Study was likely to succeed by achieving its primary endpoint. The Company utilized flawed statistical assumptions. In fact, the Company failed to demonstrate clinical differentiation from other therapies. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Regeneron, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: August 1, 2025 to May 15, 2026
DEADLINE: September 14, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. The Company gave investors the impression its Phase III Fianlimab-Libtayo Study showed signs of success and minimized risks presented by the study. The Company's study ultimately failed to achieve its primary endpoint in a statistically significant manner. Based on these facts, Regeneron's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
New York, New York--(Newsfile Corp. - July 19, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between August 1, 2025 and May 15, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/REGN.
Regeneron Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that:
the preliminary statistical assumptions underlying Regeneron's Phase III Fianlimab-Libtayo study were fundamentally flawed; the study's active treatment arm was not demonstrating meaningful clinical differentiation from standard therapies; the study was unlikely to achieve statistical significance with respect to its primary endpoint, even absent overperformance by the control arm; and as a result, the Company's statements regarding the study's design, progress, and prospects were materially false and/or misleading at all relevant times.What's Next for Regeneron Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/REGN, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Regeneron you have until September 14, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Regeneron Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Regeneron Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305581
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
[url="]The DJS Law Group[/url] reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (âRegeneronâ or âthe Companyâ) (NASD
LOS ANGELES--(BUSINESS WIRE)--Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REGN.
[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals,
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Regeneron between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - July 18, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (""Regeneron" or the "Company") (NASDAQ: REGN) and reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the true state of Regeneron's Phase III Fianlimab-Libtayo Study; notably, that its preliminary statistical assumptions were fundamentally flawed, that the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies, and that the trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm.
On April 29, 2026, Defendants disclosed that the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for "analysis of progression-free survival." On this news, Regeneron's stock price fell $45.41, or approximately 6.2%, to close at $686.36 per share on April 29, 2026.
On May 15, 2026, Regeneron issued a press release announcing that the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, Regeneron's stock price fell $68.57, or approximately 9.8%, to close at $629.68 per share on May 18, 2026.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Regeneron's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Regeneron class action, go to www.faruqilaw.com/REGN or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Regeneron Securities Class Action Lawsuit:
What is the Regeneron securities fraud lawsuit about?
Faruqi & Faruqi, LLP has filed a securities class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased Regeneron securities during the Class Period. The lawsuit alleges that Regeneron and certain of its officers made materially false and misleading statements regarding the Phase III Fianlimab-Libtayo clinical study. Specifically, the complaint alleges that defendants concealed that the study's preliminary statistical assumptions were fundamentally flawed, that the active treatment arm was allegedly failing to achieve meaningful clinical differentiation over standard therapies, and that the trial would ultimately fail to reach statistical significance on its primary endpoint. The alleged fraud is said to have come to light through two disclosures: first, on April 29, 2026, when defendants announced an expansion of patients eligible for analysis of progression-free survival - causing Regeneron's stock to fall approximately 6.2% - and then on May 15, 2026, when Regeneron announced that the Phase III trial did not reach statistical significance for its primary endpoint, causing the stock to fall an additional approximately 9.8%.
Who may be eligible to participate in the lawsuit?
Investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities on the NASDAQ between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), may be eligible to participate in this lawsuit. Eligibility to participate is not limited to those who seek appointment as lead plaintiff; any investor who purchased Regeneron securities during the Class Period and suffered a loss may potentially share in any recovery obtained on behalf of the class. Investors are encouraged to review their trading records to determine whether their purchases fall within the Class Period. Participation in the litigation does not require investors to take any active litigation role beyond filing a timely claim if a recovery is ultimately achieved.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff is a court-appointed representative who acts on behalf of all class members in directing the litigation, including working with counsel to make key strategic decisions regarding the case. Any investor who purchased Regeneron securities during the Class Period and suffered losses may move the court for appointment as lead plaintiff, but must do so no later than September 14, 2026, which is the court-established deadline for such motions. Courts generally appoint the movant with the largest financial interest in the relief sought who also satisfies the adequacy requirements of the applicable securities laws. Importantly, investors are not required to seek appointment as lead plaintiff in order to participate in or potentially share in any recovery that may result from this litigation. Those who do not seek lead plaintiff status may still submit a claim and may be eligible to receive a portion of any settlement or judgment obtained on behalf of the class.
What should investors do if they purchased Regeneron stock during the Class Period?
Investors who purchased Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026 are encouraged to promptly review their brokerage and trading records to confirm the timing and size of their purchases and any resulting losses. Investors should take steps to preserve all relevant documentation, including trade confirmations, account statements, and any communications relating to their Regeneron holdings, as such records may be material to any future claim. Given that the lead plaintiff motion deadline is September 14, 2026, investors who wish to be considered for that role should act in advance of that date. Investors may wish to consult with Faruqi & Faruqi, LLP to better understand their legal rights and options before the deadline passes. Retaining counsel or seeking lead plaintiff status is not required to participate in any potential class recovery, but timely action is advisable to preserve all available options.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Regeneron securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305568
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
LOS ANGELES--(BUSINESS WIRE)---- $REGN--REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Regeneron (REGN) To Contact Him Directly To Discuss Their Options
If you are a long-term stockholder in Regeneron common stock between August 1, 2025, and May 15, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648.
Click here to participate in the action.
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) --
What’s Happening:
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regeneron Therapeutics, Inc. (NASDAQ:REGN) on behalf of long-term stockholders following a class action complaint that was filed against Regeneron on July 16, 2026 with a Class Period from August 1, 2025, and May 15, 2026. Our investigation concerns whether the board of directors of Regeneron have breached their fiduciary duties to the company.
Details:
The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the true state of Regeneron's Phase III Fianlimab-Libtayo Study; notably, that its preliminary statistical assumptions were fundamentally flawed, that the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies, and that the trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm.
Plaintiff alleges that April 29, 2026, during Regeneron's first quarter earnings call, defendants disclosed the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for "analysis of progression-free survival." On this news, the price of Regeneron's common stock declined from a closing market price of $731.77 per share on April 28, 2026, to $686.36 per share on April 29, 2026, a decline of about 6.2% in the span of just a single day. Then, after-market on May 15, 2026, Regeneron announced that the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, the price of Regeneron's common stock declined from $698.25 per share on May 15, 2026, to $629.68 per share on May 18, 2026, a decline of about 9.8% in the span of one day.
Next Steps:
If you are a long-term stockholder of Regeneron, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026, inclusive (the “Class Period”).
The Complaint alleges that Defendants made materially false and misleading statements regarding the true state of Regeneron’s Phase III Fianlimab-Libtayo Study; notably, that its preliminary statistical assumptions were fundamentally flawed, that the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies, and that the trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Regeneron’s securities at artificially inflated prices.
The Complaint alleges that the full truth finally emerged after-market on May 15, 2026, when Regeneron issued a press release announcing that the “Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS).”
The Complaint also alleges that the investors and analysts again reacted promptly to Regeneron’s revelation. The Complaint continues to allege that the price of Regeneron’s common stock declined even further from a closing market price of $698.25 per share on May 15, 2026, Regeneron’s stock price fell to $629.68 per share on May 18, 2026, a decline of about 9.8% in the span of one day.
Investors who purchased or otherwise acquired shares of Regeneron should contact the Firm prior to the September 14, 2026 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
, /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Regeneron Therapeutics, Inc. (NASDAQ: REGN) from August 1, 2025 to May 15, 2026. Regeneron is a pharmaceutical company that discovers, invents, develops, manufactures, tests, and commercializes medicines to treat various disorders worldwide.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
The Allegations: Robbins LLP is Investigating Allegations that Regeneron Therapeutics, Inc. (REGN) Misled Investors Regarding the Viability of its Phase III Fianlimab-Libtayo Study
According to the complaint, during the relevant period, Regeneron was investigating Fianlimab, a human monoclonal antibody targeting the LAG-3 immune checkpoint receptor on T-cells. Fianlimab was pertinently being tested in combination with Libtayo in a phase 3 study to determine whether the drug combination could serve as a first-line treatment for advanced melanoma (the "Phase III Fianlimab-Libtayo Study"). The study had commenced enrollment in mid-2022.
Plaintiff alleges that defendants provided overwhelmingly positive statements to investors while, at the same time, concealing the true state of Regeneron's Phase III Fianlimab Libtayo Study; notably, that (i) its preliminary statistical assumptions were fundamentally flawed; (ii) the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies; and (iii) the trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm.
Plaintiff alleges that April 29, 2026, during Regeneron's first quarter earnings call, defendants disclosed the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for "analysis of progression-free survival." On this news, the price of Regeneron's common stock declined from a closing market price of $731.77 per share on April 28, 2026, to $686.36 per share on April 29, 2026, a decline of about 6.2% in the span of just a single day. Then, after-market on May 15, 2026, Regeneron announced that the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, the price of Regeneron's common stock declined from $698.25 per share on May 15, 2026, to $629.68 per share on May 18, 2026, a decline of about 9.8% in the span of one day.
What Now: You may be eligible to participate in the class action against Regeneron Therapeutics, Inc. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP: A recognized leader in shareholder rights litigation, Robbins LLP has helped restore more than $1 billion in value to shareholders, secured some of the largest recoveries in shareholder derivative litigation history, and achieved governance reforms at over 400 Fortune 1000 companies.
"Behind everything we do is the belief that companies should be governed responsibly, fiduciaries should be held accountable, and shareholders deserve transparency and fairness," said Brian J. Robbins, Founding Partner of Robbins LLP.
To be notified if a class action against Regeneron Therapeutics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Regeneron between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. ("“Regeneron” or the “Company”) (NASDAQ: REGN) and reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the true state of Regeneron's Phase III Fianlimab-Libtayo Study; notably, that its preliminary statistical assumptions were fundamentally flawed, that the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies, and that the trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm.
On April 29, 2026, Defendants disclosed that the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for "analysis of progression-free survival." On this news, Regeneron's stock price fell $45.41, or approximately 6.2%, to close at $686.36 per share on April 29, 2026.
On May 15, 2026, Regeneron issued a press release announcing that the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, Regeneron's stock price fell $68.57, or approximately 9.8%, to close at $629.68 per share on May 18, 2026.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Regeneron’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Regeneron class action, go to www.faruqilaw.com/REGN or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Regeneron Securities Class Action Lawsuit:
What is the Regeneron securities fraud lawsuit about?
Faruqi & Faruqi, LLP has filed a securities class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased Regeneron securities during the Class Period. The lawsuit alleges that Regeneron and certain of its officers made materially false and misleading statements regarding the Phase III Fianlimab-Libtayo clinical study. Specifically, the complaint alleges that defendants concealed that the study's preliminary statistical assumptions were fundamentally flawed, that the active treatment arm was allegedly failing to achieve meaningful clinical differentiation over standard therapies, and that the trial would ultimately fail to reach statistical significance on its primary endpoint. The alleged fraud is said to have come to light through two disclosures: first, on April 29, 2026, when defendants announced an expansion of patients eligible for analysis of progression-free survival — causing Regeneron's stock to fall approximately 6.2% — and then on May 15, 2026, when Regeneron announced that the Phase III trial did not reach statistical significance for its primary endpoint, causing the stock to fall an additional approximately 9.8%.
Who may be eligible to participate in the lawsuit?
Investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities on the NASDAQ between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), may be eligible to participate in this lawsuit. Eligibility to participate is not limited to those who seek appointment as lead plaintiff; any investor who purchased Regeneron securities during the Class Period and suffered a loss may potentially share in any recovery obtained on behalf of the class. Investors are encouraged to review their trading records to determine whether their purchases fall within the Class Period. Participation in the litigation does not require investors to take any active litigation role beyond filing a timely claim if a recovery is ultimately achieved.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff is a court-appointed representative who acts on behalf of all class members in directing the litigation, including working with counsel to make key strategic decisions regarding the case. Any investor who purchased Regeneron securities during the Class Period and suffered losses may move the court for appointment as lead plaintiff, but must do so no later than September 14, 2026, which is the court-established deadline for such motions. Courts generally appoint the movant with the largest financial interest in the relief sought who also satisfies the adequacy requirements of the applicable securities laws. Importantly, investors are not required to seek appointment as lead plaintiff in order to participate in or potentially share in any recovery that may result from this litigation. Those who do not seek lead plaintiff status may still submit a claim and may be eligible to receive a portion of any settlement or judgment obtained on behalf of the class.
What should investors do if they purchased Regeneron stock during the Class Period?
Investors who purchased Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026 are encouraged to promptly review their brokerage and trading records to confirm the timing and size of their purchases and any resulting losses. Investors should take steps to preserve all relevant documentation, including trade confirmations, account statements, and any communications relating to their Regeneron holdings, as such records may be material to any future claim. Given that the lead plaintiff motion deadline is September 14, 2026, investors who wish to be considered for that role should act in advance of that date. Investors may wish to consult with Faruqi & Faruqi, LLP to better understand their legal rights and options before the deadline passes. Retaining counsel or seeking lead plaintiff status is not required to participate in any potential class recovery, but timely action is advisable to preserve all available options.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Regeneron securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7f60c456-51b6-4096-a862-d5d3beda6cc5
Broader equities have performed so well in recent years that the dividends companies pay haven't kept pace. As a result, the S&P 500's average yield is just 1.1% right now. Thankfully, it's possible to find high-yield dividend stocks that are worth investing in. Here are three examples: Pfizer (PFE +1.27%), Novo Nordisk (NVO +1.86%), and Sanofi (SNY +1.21%). All three have faced some issues lately, but they are worth sticking with for the long haul, especially for dividend seekers. Let me explain.
Image source: Getty Images.
1. Pfizer Several headwinds -- including mediocre financial results and upcoming patent cliffs -- have pushed Pfizer's shares down significantly over the past few years. But the drugmaker hasn't suspended or decreased its payouts. As a result, Pfizer's forward dividend yield is now a juicy 7.1%. And despite the issues it has faced, it's a great time to pick up Pfizer's shares on the dip. The pharmaceutical leader boasts several products that are posting solid sales growth and should help nudge the top-line in the right direction over the medium term. The list includes Padcev, a cancer medicine, and Abrysvo, a respiratory syncytial virus vaccine.
Today's Change
(
1.27
%) $
0.32
Current Price
$
25.14
Further, the healthcare giant has a deep pipeline that should make significant progress over the next few years. Pfizer's efforts in oncology and weight-loss look particularly promising. By the end of the decade, the company should launch brand-new products in these fields to help it overcome the loss of patent exclusivity for medicines like Eliquis, an anticoagulant, and drive long-term growth.
Pfizer's financial results won't bounce back immediately, but its share price could jump well before then as the company makes solid clinical and regulatory progress with key pipeline programs. That's why investors shouldn't wait too long before initiating positions.
2. Novo Nordisk Novo Nordisk is best known for its work in the diabetes and weight loss markets, and with good reason. The company remains one of the undisputed leaders in these fields, despite recent setbacks that have sunk its stock price over the past couple of years. Novo Nordisk is well-positioned to bounce back, though. The company boasts a strong pipeline of candidates across its core therapeutic areas. Novo Nordisk's zenagamtide (amycretin) is currently undergoing phase 3 studies -- in a subcutaneous and an oral formulation -- as a potential weight loss treatment in people who are either overweight or obese.
It also posted strong phase 2 results, showing statistically significant reductions in blood sugar and weight loss in patients with type 2 diabetes.
Today's Change
(
1.86
%) $
0.94
Current Price
$
51.50
Zenagamtide could become an important drug for Novo Nordisk as it moves beyond its famous therapies, Ozempic and Wegovy. And the Denmark-based pharmaceutical leader is also inching closer to approval for CagriSema, another diabetes and weight-loss treatment. Elsewhere, Novo Nordisk is making progress in diversifying its lineup. It is particularly targeting rare blood diseases. The company recently announced positive phase 3 clinical trials for denecimig, an investigational treatment for hemophilia.
Novo Nordisk's strong position in the rapidly growing GLP-1 area and clinical progress elsewhere could allow the stock to recover. Meanwhile, Novo Nordisk offers a forward yield of 3.6% and routinely increases its payouts, making it a great pick for income seekers.
3. Sanofi Sanofi has faced some headwinds recently, including a leadership change and clinical setbacks. The stock has lagged broader equities as a result. However, there remain good reasons to be optimistic about Sanofi's long-term prospects. Here are three of them. First, the company's most important growth driver, Dupixent, is still performing very well. Dupixent is a medicine indicated for the treatment of eczema and COPD; Sanofi shares the rights to this therapy with Regeneron (REGN +2.18%). Dupixent is one of the world's best-selling drugs and is still helping Sanofi post decent sales growth.
Today's Change
(
1.21
%) $
0.53
Current Price
$
44.21
Second, Sanofi should make solid pipeline progress over the next few years. For instance, the company's frexalimab, an investigational therapy for multiple sclerosis (among other diseases), is undergoing phase 2 and phase 3 clinical trials. Frexalimab posted excellent mid-stage results and could eventually generate well over $1 billion in annual sales at its peak. Sanofi boasts several other promising candidates. Third, the company offers an attractive forward dividend yield of 5.6% and regularly increases its payouts. The dividend is safe despite recent obstacles, and the stock is worth holding for a while.
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired common stock of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) between August 1, 2025, and May 15, 2026, inclusive. You are hereby notified that the class action lawsuit Allen Cheatham v. Regeneron Pharmaceuticals, Inc., et al. (Case No. 7:26-cv-06026) has been commenced in the United States District Court for the Southern District of New York. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500. There is no cost or obligation to you.
According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Regeneron’s Phase III Fianlimab-Libtayo Study; notably, that its preliminary statistical assumptions were fundamentally flawed, that the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies, and that the trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm.
On April 29, 2026, during Regeneron’s first quarter earnings call, defendants disclosed the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for “analysis of progression-free survival.” Following this news, the price of Regeneron’s common stock declined dramatically. From a closing market price of $731.77 per share on April 28, 2026, Regeneron’s stock price fell to $686.36 per share on April 29, 2026, a decline of about 6.2% in the span of just a single day.
On May 15, 2026, Regeneron issued a press release announcing that the “Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS).” Following this news, the price of Regeneron’s common stock declined even further. From a closing market price of $698.25 per share on May 15, 2026, Regeneron’s stock price fell to $629.68 per share on May 18, 2026, a decline of about 9.8% in the span of one day.
“Our firm is committed to ensuring that investors receive full compensation for losses caused by corporate misrepresentations,” said Joseph E. Levi, a partner at Levi & Korsinsky. “We encourage REGN shareholders to step forward before the September 14, 2026 deadline so we can pursue justice on their behalf.”
If you suffered a loss in REGN common stock, you have until September 14, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004 [email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Regeneron Therapeutics, Inc. (NASDAQ: REGN) from August 1, 2025 to May 15, 2026. Regeneron is a pharmaceutical company that discovers, invents, develops, manufactures, tests, and commercializes medicines to treat various disorders worldwide.
Robbins LLP is Investigating Allegations that Regeneron Therapeutics, Inc. (REGN) Misled Investors Regarding the Viability of its Phase III Fianlimab-Libtayo Study
ShareFor more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
The Allegations: Robbins LLP is Investigating Allegations that Regeneron Therapeutics, Inc. (REGN) Misled Investors Regarding the Viability of its Phase III Fianlimab-Libtayo Study
According to the complaint, during the relevant period, Regeneron was investigating Fianlimab, a human monoclonal antibody targeting the LAG-3 immune checkpoint receptor on T-cells. Fianlimab was pertinently being tested in combination with Libtayo in a phase 3 study to determine whether the drug combination could serve as a first-line treatment for advanced melanoma (the “Phase III Fianlimab-Libtayo Study”). The study had commenced enrollment in mid-2022.
Plaintiff alleges that defendants provided overwhelmingly positive statements to investors while, at the same time, concealing the true state of Regeneron’s Phase III Fianlimab Libtayo Study; notably, that (i) its preliminary statistical assumptions were fundamentally flawed; (ii) the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies; and (iii) the trial would ultimately fail to reach statistical significance on its primary endpoint even without overperformance of the control arm.
Plaintiff alleges that April 29, 2026, during Regeneron’s first quarter earnings call, defendants disclosed the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for “analysis of progression-free survival.” On this news, the price of Regeneron’s common stock declined from a closing market price of $731.77 per share on April 28, 2026, to $686.36 per share on April 29, 2026, a decline of about 6.2% in the span of just a single day. Then, after-market on May 15, 2026, Regeneron announced that the “Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS).” On this news, the price of Regeneron’s common stock declined from $698.25 per share on May 15, 2026, to $629.68 per share on May 18, 2026, a decline of about 9.8% in the span of one day.
What Now: You may be eligible to participate in the class action against Regeneron Therapeutics, Inc. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP: A recognized leader in shareholder rights litigation, Robbins LLP has helped restore more than $1 billion in value to shareholders, secured some of the largest recoveries in shareholder derivative litigation history, and achieved governance reforms at over 400 Fortune 1000 companies.
"Behind everything we do is the belief that companies should be governed responsibly, fiduciaries should be held accountable, and shareholders deserve transparency and fairness," said Brian J. Robbins, Founding Partner of Robbins LLP.
To be notified if a class action against Regeneron Therapeutics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Regeneron (REGN - Free Report) . This company, which is in the Zacks Medical - Biomedical and Genetics industry, shows potential for another earnings beat.
This biopharmaceutical company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 9.74%.
For the last reported quarter, Regeneron came out with earnings of $9.47 per share versus the Zacks Consensus Estimate of $8.52 per share, representing a surprise of 11.15%. For the previous quarter, the company was expected to post earnings of $10.56 per share and it actually produced earnings of $11.44 per share, delivering a surprise of 8.33%.
Price and EPS Surprise
With this earnings history in mind, recent estimates have been moving higher for Regeneron. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Regeneron currently has an Earnings ESP of +0.13%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on July 30, 2026.
Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.
Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
